scholarly journals The Impact of Failure and Success Experience on Drug Development

2019 ◽  
Vol 37 (1) ◽  
pp. 74-96 ◽  
Author(s):  
Antonio Garzón‐Vico ◽  
Jan Rosier ◽  
Patrick Gibbons ◽  
Peter McNamara
Keyword(s):  
Drug Development ◽  
Success Experience ◽  
The Impact

The Impact of First-Hand and Others' Major Failure and Success Experience On Drug Development

2018 ◽  
Vol 2018 (1) ◽  
pp. 15789
Author(s):  
Antonio Garzon-Vico ◽  
Patrick T. Gibbons ◽  
Jan A. Rosier ◽  
Peter McNamara
Keyword(s):  
Drug Development ◽  
Success Experience ◽  
The Impact

scholarly journals The Impact of COVID‐19 on Pregnancy and Therapeutic Drug Development

2021 ◽  
Author(s):  
Allyah Abbas‐Hanif ◽  
Homira Rezai ◽  
S. Faraz Ahmed ◽  
Asif Ahmed
Keyword(s):  
Drug Development ◽  
Therapeutic Drug ◽  
The Impact

The impact of the written request process on drug development in childhood cancer

2013 ◽  
Vol 60 (4) ◽  
pp. 531-537 ◽  
Author(s):  
Kristen M. Snyder ◽  
Gregory Reaman ◽  
Debbie Avant ◽  
Richard Pazdur
Keyword(s):  
Drug Development ◽  
Childhood Cancer ◽  
The Impact

Australian Biotechnology: A 10-Year Study of Investor Performance

2021 ◽  
Vol 26 (4) ◽  
Author(s):  
Peter L. Molloy ◽  
Lester W. Johnson ◽  
Michael Gilding
Keyword(s):  
Drug Development ◽  
Global Financial Crisis ◽  
Critical Mass ◽  
Share Price ◽  
Annual Growth Rate ◽  
Compound Annual Growth Rate ◽  
Listed Firms ◽  
Investor Returns ◽  
The Global Financial Crisis ◽  
The Impact

A recent study assessed the investor performance of the Australian drug development biotech (DDB) sector over a 15-year period from 2003 to 2018. The current study builds on that research and extends the analysis to 2020, using a 10-year period starting 2010, to exclude the impact of the global financial crisis in 2008/09. Based on a value-weighted portfolio of all 41 DDB firms, the overall sector delivered a negative annualized return of -4.1%. Individual firm performance was also assessed using the compound annual growth rate (CAGR) in share price over the period as a measure of investor outcomes. On this basis 68% of firms produced negative CAGRs over the period, and of the 32% of firms that produced positive CAGRs, six firms produced CAGRs greater than 20% per annum and in three cases of recently-listed firms, the CAGR’s were greater than 50%. Overall however, the sector overall delivered very poor investor returns and despite a relatively large number of listed biotech firms, Australian biotechnology continues to be small and weak in terms of its contribution to global biotechnology industrialization. As such it lacks the critical mass to grow a robust bioeconomy based on drug development, which remains the standard-bearer of biotechnology industrialization.

scholarly journals The potential of microdialysis to estimate rifampicin concentrations in the lung of guinea pigs

PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0245922
Author(s):  
Faye Lanni ◽  
Neil Burton ◽  
Debbie Harris ◽  
Susan Fotheringham ◽  
Simon Clark ◽  
...  
Keyword(s):  
Drug Development ◽  
Guinea Pigs ◽  
Sampling Technique ◽  
Tissue Fluid ◽  
Experimental Conditions ◽  
Continuous Sampling ◽  
Drug Concentrations ◽  
The Impact

Optimised pre-clinical models are required for TB drug development to better predict the pharmacokinetics of anti-tuberculosis (anti-TB) drugs to shorten the time taken for novel drugs and combinations to be approved for clinical trial. Microdialysis can be used to measure unbound drug concentrations in awake freely moving animals in order to describe the pharmacokinetics of drugs in the organs as a continuous sampling technique. The aim of this work was to develop and optimise the microdialysis methodology in guinea pigs to better understand the pharmacokinetics of rifampicin in the lung. In vitro experiments were performed before progressing into in vivo studies because the recovery (concentration of the drug in the tissue fluid related to that in the collected dialysate) of rifampicin was dependent on a variety of experimental conditions. Mass spectrometry of the dialysate was used to determine the impact of flow rate, perfusion fluid and the molecular weight cut-off and membrane length of probes on the recovery of rifampicin at physiologically relevant concentrations. Following determination of probe efficiency and identification of a correlation between rifampicin concentrations in the lung and skeletal muscle, experiments were conducted to measure rifampicin in the sacrospinalis of guinea pigs using microdialysis. Lung concentrations of rifampicin were estimated from the rifampicin concentrations measured in the sacrospinalis. These studies suggest the potential usefulness of the microdialysis methodology to determine drug concentrations of selected anti-TB drugs to support new TB drug development.

Always Look on the Bright Side of Life: The Attentional Basis of Positive Affectivity

2012 ◽  
Vol 26 (2) ◽  
pp. 133-144 ◽  
Author(s):  
Ben Grafton ◽  
Christian Ang ◽  
Colin MacLeod
Keyword(s):  
Emotional Reactivity ◽  
Positive Affectivity ◽  
Positive Information ◽  
Probe Task ◽  
Bright Side ◽  
Success Experience ◽  
Attentional Selectivity ◽  
The Impact ◽  
Bias Modification

There is now reliable evidence that heightened positive affectivity is associated with a distinctive pattern of attentional selectivity, favouring emotionally positive information. While this has invited speculation that differential attentional responding to positive information may directly contribute to the determination of this emotional temperament, the causal basis of their association as yet remains unknown. We addressed this issue by experimentally manipulating selective attentional response to positive information, using a cognitive bias modification variant of the attentional probe task, and examining the impact of this attentional manipulation on positive emotional reactivity to a subsequent success experience. The findings support the hypothesis that individual differences in selective attentional response to positive information can make a causal contribution to variation in positive affectivity. Copyright © 2012 John Wiley & Sons, Ltd.

Role of Guidance and Policy in Enhancing the Impact of Clinical Pharmacology in Drug Development, Regulation, and Use

2020 ◽  
Vol 108 (4) ◽  
pp. 710-715
Author(s):  
Rajanikanth Madabushi ◽  
Elimika Pfuma Fletcher ◽  
Jeffry Florian ◽  
Lauren Milligan ◽  
Anuradha Ramamoorthy ◽  
...  
Keyword(s):  
Clinical Pharmacology ◽  
Drug Development ◽  
The Impact ◽  
Development Regulation
Sign in / Sign up

Export Citation Format

Share Document